Respiratory Cancers & Neoplasms: How VA Rates Lung & Airway Tumors

Under 38 CFR 4.97, Diagnostic Code 6819 governs malignant neoplasms of the respiratory system, including non-small cell lung cancer, small cell lung cancer, tracheal tumors, and bronchial carcinoma. When a veteran is diagnosed with an active respiratory malignancy, the VA assigns a temporary 100% disability evaluation. This total disability rating continues throughout the entire duration of active cancer treatment, including chemotherapy, immunotherapy, radiation therapy, or surgical intervention.

The rating schedule provides a mandatory protection period following treatment completion: the 100% disability evaluation continues for six months following the cessation of all active therapeutic treatment. At the conclusion of this six-month window, the VA conducts a mandatory C&P re-examination to determine whether the malignancy is in complete remission. If remission is verified, the veteran's condition is re-evaluated based on permanent residual impairment, such as reduced lung capacity from lobectomy or radiation-induced pulmonary fibrosis.

The PACT Act of 2022 established historic presumptive service connection for all respiratory cancers of any type for exposed veterans. Covered conditions include lung cancer, bronchial cancer, laryngeal cancer, pharyngeal cancer, and tracheal cancer. Veterans who served in qualifying locations during Vietnam, the Gulf War, or post-9/11 operations in Southwest Asia are entitled to service connection without needing to prove a medical nexus between their military service and cancer diagnosis.

Benign neoplasms of the respiratory system, such as hamartomas, bronchial adenomas, or tracheal polyps, are evaluated under Diagnostic Code 6820 in 38 CFR 4.97. Benign tumors are not rated at a temporary 100%. Instead, the regulation directs that benign neoplasms be rated based on their actual functional impairment: evaluated as obstructive lung disease, restrictive lung disease, or chronic pleurisy, depending on the predominant physiological impairment documented on pulmonary testing.

To expedite adjudication of a respiratory cancer claim, the claims folder must include a definitive pathology report confirming malignancy (such as bronchoscopic biopsy, fine needle aspiration, or surgical pathology), clinical oncology treatment records establishing the treatment timeline and ongoing therapeutic modalities, and deployment records establishing service in a qualifying PACT Act or Agent Orange geographic theater.